SIMILAR PATTERNS OF AMINO ACIDS FOR 3BBT_B_FMMB91_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 428 LEU A 460 THR A 474 GLY A 480 LEU A 528 ASP A 539 PHE A 540	None	0.74A	3bbtB-1k2pA: 29.3	3bbtB-1k2pA: 34.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 416 ALA A 428 MET A 449 LEU A 460 GLY A 480 LEU A 528 ASP A 539 PHE A 540	None	0.74A	3bbtB-1k2pA: 29.3	3bbtB-1k2pA: 34.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 LEU A 251 THR A 266 GLY A 272 LEU A 321	None	0.68A	3bbtB-1k9aA: 30.2	3bbtB-1k9aA: 25.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 86 ALA A 99 GLY A 153 LEU A 201 ASP A 212 PHE A 213	ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) MG A 536 (-3.3A) 5EA A1001 (-3.6A)	0.29A	3bbtB-1s9iA: 24.3	3bbtB-1s9iA: 25.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 377 ALA A 389 LEU A 421 GLY A 441 LEU A 489 ASP A 500 PHE A 501	None	0.70A	3bbtB-1snxA: 24.4	3bbtB-1snxA: 33.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 603 ALA A 621 LEU A 656 THR A 670 GLY A 676 LEU A 799	STI A 3 ( 4.6A) STI A 3 (-3.5A) None STI A 3 (-3.2A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.66A	3bbtB-1t46A: 25.7	3bbtB-1t46A: 29.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL X 25 ALA X 37 LEU X 69 THR X 82 GLY X 88 LEU X 137	STU X 902 ( 4.8A) STU X 902 (-3.1A) None STU X 902 (-4.1A) STU X 902 (-3.5A) STU X 902 (-4.4A)	0.66A	3bbtB-2dq7X: 23.8	3bbtB-2dq7X: 36.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	VAL A 281 ALA A 293 MET A 314 LEU A 325 THR A 338 GLY A 344 LEU A 393 ASP A 404 PHE A 405 LEU A 407	H8H A 534 (-4.4A) H8H A 534 (-3.2A) None None H8H A 534 (-3.1A) H8H A 534 (-3.3A) H8H A 534 (-4.5A) H8H A 534 (-4.2A) None None	0.84A	3bbtB-2h8hA: 32.9	3bbtB-2h8hA: 23.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	VAL A 281 ALA A 293 MET A 314 LEU A 325 THR A 338 GLY A 344 LEU A 393 ASP A 404 PHE A 405	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None None QUE A 1 (-3.3A) QUE A 1 (-3.0A) QUE A 1 (-4.4A) None None	0.83A	3bbtB-2hckA: 31.7	3bbtB-2hckA: 25.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 281 MET A 314 THR A 338 GLY A 344 LEU A 393 ASP A 404 PHE A 405 LEU A 407	QUE A 1 ( 4.8A) None QUE A 1 (-3.3A) QUE A 1 (-3.0A) QUE A 1 (-4.4A) None None None	1.09A	3bbtB-2hckA: 31.7	3bbtB-2hckA: 25.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 259 ALA A 271 LEU A 303 THR A 316 GLY A 322 LEU A 371	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) None 1BM A 499 (-3.2A) 1BM A 499 (-3.5A) 1BM A 499 (-4.4A)	0.59A	3bbtB-2hk5A: 24.1	3bbtB-2hk5A: 34.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 256 ALA A 269 LEU A 301 THR A 315 GLY A 321 LEU A 370	GIN A 600 ( 4.7A) GIN A 600 (-3.1A) None GIN A 600 (-3.4A) None GIN A 600 (-4.7A)	0.63A	3bbtB-2hz0A: 29.6	3bbtB-2hz0A: 34.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	9	VAL A 352 ALA A 367 MET A 390 LEU A 401 GLY A 418 LEU A 468 ASP A 479 PHE A 480 LEU A 482	ANP A 615 (-4.5A) ANP A 615 (-3.3A) None None ANP A 615 ( 4.0A) ANP A 615 (-4.7A) MG A 614 ( 3.2A) None None	1.16A	3bbtB-2ozoA: 31.7	3bbtB-2ozoA: 23.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	VAL A 352 ALA A 367 MET A 390 LEU A 401 GLY A 419 LEU A 468 ASP A 479 PHE A 480	ANP A 615 (-4.5A) ANP A 615 (-3.3A) None None None ANP A 615 (-4.7A) MG A 614 ( 3.2A) None	0.89A	3bbtB-2ozoA: 31.7	3bbtB-2ozoA: 23.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	9	VAL A 352 ALA A 367 MET A 390 LEU A 401 GLY A 420 LEU A 468 ASP A 479 PHE A 480 LEU A 482	ANP A 615 (-4.5A) ANP A 615 (-3.3A) None None ANP A 615 ( 3.9A) ANP A 615 (-4.7A) MG A 614 ( 3.2A) None None	0.80A	3bbtB-2ozoA: 31.7	3bbtB-2ozoA: 23.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	7	VAL A 33 ALA A 46 LEU A 89 LEU A 105 GLY A 109 LEU A 156 THR A 166	ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None None ATP A 381 ( 4.8A) ATP A 381 ( 4.6A)	0.39A	3bbtB-2phkA: 21.7	3bbtB-2phkA: 25.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	7	VAL A 33 ALA A 46 LEU A 105 GLY A 109 LEU A 156 THR A 166 PHE A 168	ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None ATP A 381 ( 4.8A) ATP A 381 ( 4.6A) None	0.80A	3bbtB-2phkA: 21.7	3bbtB-2phkA: 25.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	VAL B 55 ALA B 67 LEU B 100 GLY B 120 LEU B 171 THR B 181	None	0.55A	3bbtB-2qkwB: 18.3	3bbtB-2qkwB: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 204 ALA A 215 THR A 265 GLY A 271 LEU A 328 ASP A 339 PHE A 340	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) ADE A 488 (-4.3A) ADE A 488 ( 4.1A) ADE A 488 (-4.4A) None None	0.90A	3bbtB-2qluA: 24.5	3bbtB-2qluA: 23.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 LEU A 685 THR A 699 GLY A 705 LEU A 753	BME A 1 (-4.9A) PTR A 701 ( 4.7A) None None None None	0.69A	3bbtB-2qobA: 25.1	3bbtB-2qobA: 35.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	MET A 772 LEU A 783 THR A 796 GLY A 802 LEU A 850 THR A 860 ASP A 861 PHE A 862 LEU A 864	GW7 A 1 ( 3.8A) GW7 A 1 (-3.9A) GW7 A 1 (-4.0A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A) GW7 A 1 (-3.8A) GW7 A 1 ( 4.7A)	0.81A	3bbtB-2r4bA: 38.7	3bbtB-2r4bA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	11	VAL A 732 ALA A 749 LEU A 783 THR A 796 LEU A 798 GLY A 802 LEU A 850 THR A 860 ASP A 861 PHE A 862 LEU A 864	GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-4.0A) GW7 A 1 (-4.5A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-3.5A) GW7 A 1 (-4.1A) GW7 A 1 (-3.8A) GW7 A 1 ( 4.7A)	0.64A	3bbtB-2r4bA: 38.7	3bbtB-2r4bA: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 234 ALA A 247 LEU A 303 GLY A 307 LEU A 354 THR A 367	XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.1A) XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A) XK9 A1511 (-3.7A)	0.58A	3bbtB-2xk9A: 20.6	3bbtB-2xk9A: 26.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 LEU A 685 THR A 699 GLY A 705 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) None Q9G A1898 (-3.5A) Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.58A	3bbtB-2xyuA: 19.2	3bbtB-2xyuA: 34.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 38 ALA A 51 LEU A 93 LEU A 109 GLY A 113 LEU A 160	None B49 A1294 (-3.2A) None B49 A1294 ( 4.7A) B49 A1294 (-3.6A) B49 A1294 (-4.4A)	0.38A	3bbtB-2y7jA: 22.2	3bbtB-2y7jA: 21.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 38 ALA A 51 LEU A 109 GLY A 113 LEU A 160 ASP A 171 PHE A 172	None B49 A1294 (-3.2A) B49 A1294 ( 4.7A) B49 A1294 (-3.6A) B49 A1294 (-4.4A) B49 A1294 (-4.2A) None	0.87A	3bbtB-2y7jA: 22.2	3bbtB-2y7jA: 21.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 76 ALA A 92 LEU A 127 GLY A 147 LEU A 194 THR A 204 PHE A 206	None STU A 1 (-3.3A) None STU A 1 ( 3.9A) STU A 1 (-4.6A) STU A 1 (-3.6A) None	0.81A	3bbtB-2z7rA: 21.9	3bbtB-2z7rA: 24.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 492 ALA A 512 GLY A 567 LEU A 630 ASP A 641 PHE A 642 LEU A 644	None C4F A 1 (-3.3A) None C4F A 1 (-4.6A) C4F A 1 (-4.5A) C4F A 1 ( 4.5A) None	1.06A	3bbtB-3c4fA: 29.6	3bbtB-3c4fA: 33.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 LEU A 251 THR A 266 GLY A 272 LEU A 321	None	0.68A	3bbtB-3d7uA: 24.8	3bbtB-3d7uA: 33.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dtc	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 158 ALA A 169 LEU A 206 GLY A 226 LEU A 275 THR A 293 PHE A 295	VIN A6331 (-4.7A) VIN A6331 (-3.4A) None VIN A6331 (-3.4A) VIN A6331 (-4.5A) VIN A6331 (-3.6A) None	0.59A	3bbtB-3dtcA: 21.4	3bbtB-3dtcA: 31.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dxn	CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3 (Toxoplasma gondii)	PF00069 (Pkinase)	8	VAL A 37 ALA A 50 LEU A 86 GLY A 106 LEU A 153 ASP A 167 PHE A 168 LEU A 170	None	0.76A	3bbtB-3dxnA: 25.4	3bbtB-3dxnA: 26.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 439 ALA A 455 LEU A 489 LEU A 504 GLY A 508 LEU A 556	AGS A 999 (-4.6A) AGS A 999 (-3.6A) None AGS A 999 (-4.4A) None AGS A 999 (-4.5A)	0.62A	3bbtB-3fzpA: 30.3	3bbtB-3fzpA: 37.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	8	VAL A 234 ALA A 247 LEU A 303 GLY A 307 LEU A 354 THR A 367 ASP A 368 PHE A 369	None	0.72A	3bbtB-3i6uA: 22.6	3bbtB-3i6uA: 22.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 704 LEU A 755 THR A 768 GLY A 774 LEU A 822 ASP A 833 PHE A 834	ANP A 1 (-3.9A) None ANP A 1 ( 4.8A) ANP A 1 ( 4.9A) ANP A 1 (-4.7A) MG A1001 ( 3.1A) None	0.53A	3bbtB-3kexA: 32.4	3bbtB-3kexA: 58.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 THR A 713 GLY A 719 LEU A 767 ASP A 778 PHE A 779	None None None GOL A 403 (-3.4A) None None None	0.99A	3bbtB-3kulA: 30.6	3bbtB-3kulA: 32.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	11	ALA A 719 MET A 742 LEU A 753 THR A 766 LEU A 768 GLY A 772 LEU A 820 THR A 830 ASP A 831 PHE A 832 LEU A 834	ITI A 1 (-2.9A) ITI A 1 (-3.4A) ITI A 1 (-3.8A) ITI A 1 (-3.8A) ITI A 1 (-4.8A) ITI A 1 (-3.5A) ITI A 1 (-4.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.6A) ITI A 1 (-3.6A) None	0.92A	3bbtB-3lzbA: 37.8	3bbtB-3lzbA: 69.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	11	VAL A 702 ALA A 719 MET A 742 LEU A 753 THR A 766 LEU A 768 LEU A 820 THR A 830 ASP A 831 PHE A 832 LEU A 834	ITI A 1 (-4.8A) ITI A 1 (-2.9A) ITI A 1 (-3.4A) ITI A 1 (-3.8A) ITI A 1 (-3.8A) ITI A 1 (-4.8A) ITI A 1 (-4.6A) ITI A 1 (-3.8A) ITI A 1 ( 4.6A) ITI A 1 (-3.6A) None	0.92A	3bbtB-3lzbA: 37.8	3bbtB-3lzbA: 69.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pg1	MITOGEN-ACTIVATED PROTEIN KINASE, PUTATIVE (MAP KINASE-LIKE PROTEIN) (Leishmania major)	PF00069 (Pkinase)	7	ALA A 49 THR A 112 LEU A 114 LEU A 165 ASP A 176 PHE A 177 LEU A 179	None	0.96A	3bbtB-3pg1A: 19.8	3bbtB-3pg1A: 26.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pls	MACROPHAGE-STIMULATI NG PROTEIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A1096 ALA A1112 MET A1135 LEU A1146 GLY A1167 ASP A1226 PHE A1227 LEU A1229	ANP A1358 (-4.4A) ANP A1358 ( 3.8A) None None None MG A 1 ( 3.2A) None None	0.71A	3bbtB-3plsA: 31.2	3bbtB-3plsA: 35.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 751 LEU A 785 LEU A 800 GLY A 804 LEU A 852 THR A 862 ASP A 863 PHE A 864	03Q A 1 (-3.1A) 03Q A 1 (-3.1A) 03Q A 1 (-4.6A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A) 03Q A 1 (-3.3A) 03Q A 1 (-4.0A) 03Q A 1 (-4.2A)	0.92A	3bbtB-3pp0A: 31.0	3bbtB-3pp0A: 73.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ALA A 751 LEU A 785 THR A 798 LEU A 800 GLY A 804 LEU A 852 THR A 862 PHE A 864	03Q A 1 (-3.1A) 03Q A 1 (-3.1A) 03Q A 1 (-4.1A) 03Q A 1 (-4.6A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A) 03Q A 1 (-3.3A) 03Q A 1 (-4.2A)	0.81A	3bbtB-3pp0A: 31.0	3bbtB-3pp0A: 73.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 734 ALA A 751 LEU A 785 LEU A 800 GLY A 804 LEU A 852 THR A 862 ASP A 863	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-3.1A) 03Q A 1 (-4.6A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A) 03Q A 1 (-3.3A) 03Q A 1 (-4.0A)	0.68A	3bbtB-3pp0A: 31.0	3bbtB-3pp0A: 73.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 734 ALA A 751 LEU A 785 THR A 798 LEU A 800 GLY A 804 LEU A 852 THR A 862	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-3.1A) 03Q A 1 (-4.1A) 03Q A 1 (-4.6A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A) 03Q A 1 (-3.3A)	0.40A	3bbtB-3pp0A: 31.0	3bbtB-3pp0A: 73.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 734 ALA A 751 MET A 774 THR A 798 LEU A 800 GLY A 804 LEU A 852 THR A 862	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.5A) 03Q A 1 (-4.1A) 03Q A 1 (-4.6A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A) 03Q A 1 (-3.3A)	1.12A	3bbtB-3pp0A: 31.0	3bbtB-3pp0A: 73.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	7	VAL A 565 ALA A 576 THR A 625 GLY A 631 LEU A 683 ASP A 694 PHE A 695	STU A 1 (-4.9A) STU A 1 (-3.3A) STU A 1 (-4.1A) STU A 1 (-3.2A) STU A 1 (-4.3A) STU A 1 (-3.5A) None	0.89A	3bbtB-3ppzA: 28.0	3bbtB-3ppzA: 30.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	VAL A 303 ALA A 315 LEU A 349 GLY A 369 LEU A 423 ASP A 434	None	0.69A	3bbtB-3ulzA: 22.0	3bbtB-3ulzA: 27.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 83 ALA A 96 GLY A 150 LEU A 198 ASP A 209 PHE A 210	ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 ( 4.3A) ANP A 401 (-4.8A) MG A 402 (-3.2A) CHU A 403 (-3.8A)	0.37A	3bbtB-3wigA: 17.4	3bbtB-3wigA: 25.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 GLY A 922 LEU A1035 ASP A1046 PHE A1047 LEU A1049	LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.4A) LEV A1201 (-3.3A) LEV A1201 ( 4.5A)	0.80A	3bbtB-3wzdA: 29.5	3bbtB-3wzdA: 32.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 LEU A 889 GLY A 922 LEU A1035 ASP A1046 LEU A1049	LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 ( 4.4A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.4A) LEV A1201 ( 4.5A)	1.02A	3bbtB-3wzdA: 29.5	3bbtB-3wzdA: 32.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 633 ALA A 649 LEU A 683 THR A 697 GLY A 703 LEU A 751	None	0.65A	3bbtB-3zfxA: 31.1	3bbtB-3zfxA: 35.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	VAL A 222 ALA A 233 THR A 283 GLY A 289 LEU A 343 ASP A 354	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 (-3.6A) TAK A1507 (-3.5A) TAK A1507 (-4.7A) TAK A1507 (-3.5A)	0.61A	3bbtB-4c02A: 18.9	3bbtB-4c02A: 23.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	7	VAL A 254 ALA A 267 GLY A 324 LEU A 371 THR A 381 ASP A 382 PHE A 383	None	0.97A	3bbtB-4c0tA: 20.2	3bbtB-4c0tA: 15.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	VAL A 575 ALA A 588 LEU A 622 LEU A 638 GLY A 642 LEU A 690	GUI A 901 (-4.5A) GUI A 901 (-3.4A) None GUI A 901 (-4.4A) GUI A 901 (-3.5A) GUI A 901 (-4.3A)	0.67A	3bbtB-4e93A: 31.2	3bbtB-4e93A: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	7	VAL A 575 ALA A 588 LEU A 638 GLY A 642 LEU A 690 ASP A 701 PHE A 702	GUI A 901 (-4.5A) GUI A 901 (-3.4A) GUI A 901 (-4.4A) GUI A 901 (-3.5A) GUI A 901 (-4.3A) GUI A 901 ( 4.1A) None	0.93A	3bbtB-4e93A: 31.2	3bbtB-4e93A: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	8	VAL A 385 ALA A 400 MET A 424 GLY A 454 LEU A 501 ASP A 512 PHE A 513 LEU A 515	ANP A 701 (-4.1A) ANP A 701 (-3.3A) None ANP A 701 ( 4.2A) ANP A 701 (-4.5A) MG A 702 ( 3.1A) None None	0.61A	3bbtB-4fl3A: 32.9	3bbtB-4fl3A: 22.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A1130 ALA A1148 LEU A1198 GLY A1202 LEU A1256 PHE A1271	0UV A1501 (-4.5A) 0UV A1501 (-3.4A) 0UV A1501 ( 4.8A) 0UV A1501 (-3.6A) 0UV A1501 (-4.6A) None	0.69A	3bbtB-4fodA: 28.6	3bbtB-4fodA: 32.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fr4	SERINE/THREONINE-PRO TEIN KINASE 32A (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 37 ALA A 50 LEU A 86 LEU A 102 GLY A 106 THR A 163	STU A 401 ( 4.9A) STU A 401 (-3.2A) None STU A 401 (-4.4A) STU A 401 ( 3.7A) STU A 401 (-3.8A)	0.70A	3bbtB-4fr4A: 19.8	3bbtB-4fr4A: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fr4	SERINE/THREONINE-PRO TEIN KINASE 32A (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 37 ALA A 50 LEU A 102 GLY A 106 LEU A 153 THR A 163 PHE A 165	STU A 401 ( 4.9A) STU A 401 (-3.2A) STU A 401 (-4.4A) STU A 401 ( 3.7A) STU A 401 (-4.7A) STU A 401 (-3.8A) None	0.81A	3bbtB-4fr4A: 19.8	3bbtB-4fr4A: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g3f	NF-KAPPA-BETA-INDUCI NG KINASE (Mus musculus)	PF00069 (Pkinase)	7	VAL A 416 ALA A 429 LEU A 457 LEU A 473 GLY A 477 LEU A 524 PHE A 537	0WB A 701 (-4.4A) 0WB A 701 (-3.3A) None 0WB A 701 (-4.3A) 0WB A 701 ( 4.5A) 0WB A 701 (-4.3A) None	0.99A	3bbtB-4g3fA: 23.3	3bbtB-4g3fA: 24.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	9	VAL A 140 ALA A 156 MET A 181 LEU A 192 GLY A 211 LEU A 259 ASP A 270 PHE A 271 LEU A 273	None	0.53A	3bbtB-4hzsA: 23.7	3bbtB-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	9	VAL A 140 ALA A 156 MET A 181 LEU A 192 LEU A 207 GLY A 211 LEU A 259 ASP A 270 LEU A 273	None	0.73A	3bbtB-4hzsA: 23.7	3bbtB-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	9	VAL A 140 ALA A 156 MET A 181 LEU A 192 THR A 205 GLY A 211 LEU A 259 ASP A 270 PHE A 271	None	0.69A	3bbtB-4hzsA: 23.7	3bbtB-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	9	VAL A 140 ALA A 156 MET A 181 LEU A 192 THR A 205 LEU A 207 GLY A 211 LEU A 259 ASP A 270	None	0.84A	3bbtB-4hzsA: 23.7	3bbtB-4hzsA: 36.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 140 ALA A 156 LEU A 192 THR A 205 LEU A 207 GLY A 211 LEU A 259	1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 ( 3.8A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.9A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.77A	3bbtB-4id7A: 30.2	3bbtB-4id7A: 36.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 140 ALA A 156 THR A 205 LEU A 207 GLY A 211 LEU A 259 PHE A 271	1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.9A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A) 1G0 A 401 ( 4.8A)	0.97A	3bbtB-4id7A: 30.2	3bbtB-4id7A: 36.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 414 ALA A 427 LEU A 455 LEU A 471 GLY A 475 LEU A 522 PHE A 535	T28 A 701 (-4.7A) T28 A 701 (-3.0A) None T28 A 701 ( 4.8A) T28 A 701 ( 3.0A) T28 A 701 (-3.9A) None	0.97A	3bbtB-4idtA: 22.8	3bbtB-4idtA: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 414 ALA A 427 LEU A 455 LEU A 471 LEU A 522 ASP A 534 PHE A 535	T28 A 701 (-4.7A) T28 A 701 (-3.0A) None T28 A 701 ( 4.8A) T28 A 701 (-3.9A) T28 A 701 ( 3.4A) None	1.02A	3bbtB-4idtA: 22.8	3bbtB-4idtA: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	VAL A 281 ALA A 293 MET A 314 LEU A 325 GLY A 344 LEU A 393 ASP A 404 PHE A 405 LEU A 407	0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) None None 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A) 0J9 A 601 (-3.1A) None None	0.63A	3bbtB-4k11A: 33.0	3bbtB-4k11A: 25.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	10	VAL A 36 ALA A 49 MET A 65 LEU A 76 THR A 95 GLY A 101 LEU A 150 ASP A 161 PHE A 162 LEU A 164	ANP A 401 (-4.5A) ANP A 401 (-3.1A) None None ANP A 401 (-3.8A) None ANP A 401 (-4.8A) MG A 403 ( 3.1A) None None	0.75A	3bbtB-4m69A: 27.3	3bbtB-4m69A: 25.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 54 ALA A 67 THR A 123 LEU A 125 GLY A 128 LEU A 180 PHE A 192	None SIN A 401 ( 3.7A) None SIN A 401 ( 4.8A) SIN A 401 (-3.5A) SIN A 401 ( 4.5A) None	0.77A	3bbtB-4o38A: 18.5	3bbtB-4o38A: 24.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 627 ALA A 644 LEU A 678 THR A 692 GLY A 698 LEU A 746	None	0.61A	3bbtB-4p2kA: 29.9	3bbtB-4p2kA: 35.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4uy9	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 158 ALA A 169 GLY A 226 LEU A 275 THR A 293 ASP A 294 PHE A 295	None	0.74A	3bbtB-4uy9A: 27.1	3bbtB-4uy9A: 33.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4uya	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 138 ALA A 149 GLY A 206 LEU A 270 THR A 288 PHE A 290	AGS A1438 (-4.4A) AGS A1438 (-3.4A) None AGS A1438 (-4.7A) AGS A1438 ( 4.7A) None	0.62A	3bbtB-4uyaA: 26.6	3bbtB-4uyaA: 34.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	6	VAL B 275 ALA B 288 LEU B 320 THR B 334 GLY B 340 LEU B 389	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.63A	3bbtB-4xeyB: 25.0	3bbtB-4xeyB: 29.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	VAL A 416 ALA A 428 MET A 449 LEU A 460 THR A 474 GLY A 480 LEU A 528 ASP A 539 PHE A 540 LEU A 542	None	0.87A	3bbtB-4xi2A: 30.9	3bbtB-4xi2A: 25.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	9	VAL A 416 ALA A 428 MET A 449 LEU A 460 THR A 474 GLY A 480 LEU A 528 ASP A 539 PHE A 540	746 A 702 ( 4.3A) 746 A 702 (-2.4A) None None 746 A 702 (-3.7A) 746 A 702 (-3.6A) 746 A 702 (-4.4A) 746 A 702 (-3.7A) None	0.75A	3bbtB-4y93A: 31.5	3bbtB-4y93A: 24.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yc6	CYCLIN-DEPENDENT KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 LEU A 66 LEU A 135 ASP A 146 PHE A 147	None	0.60A	3bbtB-4yc6A: 24.6	3bbtB-4yc6A: 24.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 477 ALA A 488 THR A 539 GLY A 545 LEU A 595 ASP A 606 PHE A 607	None 4CV A 801 (-3.5A) 4CV A 801 (-2.8A) 4CV A 801 ( 4.0A) 4CV A 801 (-4.4A) 4CV A 801 (-3.5A) None	1.10A	3bbtB-4yffA: 24.9	3bbtB-4yffA: 27.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 492 ALA A 512 GLY A 567 LEU A 630 ASP A 641 PHE A 642 LEU A 644	38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 (-3.4A) 38O A1769 (-4.6A) 38O A1769 (-4.0A) EDO A1766 (-3.7A) None	0.85A	3bbtB-5a46A: 27.2	3bbtB-5a46A: 34.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5d7a	TRAF2 AND NCK-INTERACTING PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 39 ALA A 52 GLY A 111 LEU A 160 ASP A 171 PHE A 172	VAL A 39 (-0.6A) ALA A 52 (-0.0A) GLY A 111 (-0.0A) LEU A 160 (-0.6A) ASP A 171 ( 0.5A) PHE A 172 ( 1.3A)	0.55A	3bbtB-5d7aA: 24.1	3bbtB-5d7aA: 25.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 607 ALA A 625 LEU A 660 THR A 674 GLY A 680 LEU A 825	748 A1001 ( 4.7A) 748 A1001 (-3.7A) None 748 A1001 (-3.2A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.64A	3bbtB-5grnA: 23.6	3bbtB-5grnA: 30.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	6	VAL A 28 ALA A 41 LEU A 76 LEU A 92 GLY A 96 LEU A 143	ADP A 301 (-3.7A) ADP A 301 (-3.5A) None ADP A 301 ( 4.8A) None ADP A 301 (-4.7A)	0.66A	3bbtB-5hu3A: 23.0	3bbtB-5hu3A: 25.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 743 LEU A 792 GLY A 796 LEU A 844 THR A 854 ASP A 855 PHE A 856	6HJ A1101 (-3.1A) 6HJ A1101 ( 4.9A) 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A) 6HJ A1101 (-4.3A) None	0.89A	3bbtB-5j9zA: 32.8	3bbtB-5j9zA: 77.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 726 ALA A 743 LEU A 777 LEU A 792 GLY A 796 LEU A 844 THR A 854	6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) None 6HJ A1101 ( 4.9A) 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A)	0.65A	3bbtB-5j9zA: 32.8	3bbtB-5j9zA: 77.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 726 ALA A 743 LEU A 792 GLY A 796 LEU A 844 THR A 854 PHE A 856	6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 ( 4.9A) 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A) 6HJ A1101 (-3.9A) None	0.85A	3bbtB-5j9zA: 32.8	3bbtB-5j9zA: 77.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 404 ALA A 417 LEU A 451 LEU A 467 GLY A 471 LEU A 518	GUI A 701 (-4.4A) GUI A 701 ( 3.9A) None GUI A 701 ( 4.7A) GUI A 701 (-3.6A) GUI A 701 (-4.4A)	0.55A	3bbtB-5jznA: 22.1	3bbtB-5jznA: 25.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kkr	KINASE SUPPRESSOR OF RAS 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL B 680 ALA B 690 THR B 739 LEU B 741 THR B 802 PHE B 804	6U7 B1001 ( 4.3A) 6U7 B1001 (-3.6A) 6U7 B1001 (-4.0A) 6U7 B1001 (-4.6A) 6U7 B1001 (-3.6A) 6U7 B1001 (-3.8A)	0.65A	3bbtB-5kkrB: 24.7	3bbtB-5kkrB: 27.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5loh	SERINE/THREONINE-PRO TEIN KINASE GREATWALL,SERINE/THR EONINE-PROTEIN KINASE GREATWALL (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 49 ALA A 60 LEU A 96 GLY A 116 LEU A 163 THR A 173 PHE A 175	None STU A 901 (-3.3A) None STU A 901 (-3.5A) STU A 901 (-4.5A) STU A 901 (-3.5A) None	0.63A	3bbtB-5lohA: 17.7	3bbtB-5lohA: 24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vcx	MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 124 ALA A 137 LEU A 173 THR A 187 LEU A 189 GLY A 191 ASP A 251 PHE A 252	H8H A 401 (-4.7A) H8H A 401 (-3.3A) None H8H A 401 (-3.5A) None H8H A 401 (-4.4A) EDO A 402 ( 2.9A) None	1.29A	3bbtB-5vcxA: 17.3	3bbtB-5vcxA: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	9	VAL A 899 ALA A 917 MET A 938 THR A 963 GLY A 969 LEU A1017 THR A1027 ASP A1028 PHE A1029	ANP A1201 (-4.4A) ANP A1201 (-3.3A) None ANP A1201 (-3.9A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A) ANP A1201 ( 4.9A) MG A1202 ( 3.0A) None	0.56A	3bbtB-5wnoA: 35.4	3bbtB-5wnoA: 17.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	9	VAL A 899 ALA A 917 THR A 963 GLY A 969 LEU A1017 THR A1027 ASP A1028 PHE A1029 LEU A1031	ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.9A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A) ANP A1201 ( 4.9A) MG A1202 ( 3.0A) None None	0.73A	3bbtB-5wnoA: 35.4	3bbtB-5wnoA: 17.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xzw	SERINE/THREONINE-PRO TEIN KINASE RAD53 (Saccharomyces cerevisiae)	no annotation	7	VAL A 212 ALA A 225 GLY A 279 LEU A 326 THR A 338 ASP A 339 PHE A 340	None	1.04A	3bbtB-5xzwA: 18.9	3bbtB-5xzwA: 20.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xzw	SERINE/THREONINE-PRO TEIN KINASE RAD53 (Saccharomyces cerevisiae)	no annotation	7	VAL A 212 LEU A 248 GLY A 279 LEU A 326 THR A 338 ASP A 339 PHE A 340	None	1.32A	3bbtB-5xzwA: 18.9	3bbtB-5xzwA: 20.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	7	VAL A 41 ALA A 54 MET A 74 GLY A 105 LEU A 153 ASP A 164 PHE A 165	ANP A 501 (-4.4A) ANP A 501 ( 3.7A) None ANP A 501 ( 4.0A) ANP A 501 (-4.6A) MG A 502 ( 3.1A) None	0.60A	3bbtB-6ao5A: 23.6	3bbtB-6ao5A: 26.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b2q	SERINE/THREONINE-PRO TEIN KINASE PKNA (Mycobacterium tuberculosis)	no annotation	7	VAL A 27 ALA A 40 LEU A 97 GLY A 100 LEU A 148 THR A 158 PHE A 160	CJJ A 301 (-4.6A) CJJ A 301 (-3.5A) None CJJ A 301 (-4.2A) CJJ A 301 (-4.5A) CJJ A 301 (-3.1A) None	1.17A	3bbtB-6b2qA: 23.5	3bbtB-6b2qA: 13.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	6	VAL A 179 ALA A 192 LEU A 251 LEU A 269 GLY A 273 LEU A 319	BI9 A 501 ( 4.8A) BI9 A 501 (-3.3A) None BI9 A 501 (-4.4A) BI9 A 501 (-3.3A) BI9 A 501 (-4.7A)	0.55A	3bbtB-6bqlA: 20.9	3bbtB-6bqlA: 12.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	6	VAL A 142 ALA A 155 LEU A 214 LEU A 232 GLY A 236 LEU A 282	H1N A 501 (-4.4A) H1N A 501 (-3.4A) None H1N A 501 (-4.3A) H1N A 501 (-3.6A) H1N A 501 (-4.8A)	0.42A	3bbtB-6ccfA: 23.2	3bbtB-6ccfA: 13.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	6	VAL A 179 ALA A 192 LEU A 251 LEU A 269 GLY A 273 LEU A 319	F6J A 501 (-4.6A) F6J A 501 (-3.4A) None F6J A 501 ( 4.4A) F6J A 501 ( 3.7A) F6J A 501 (-4.5A)	0.64A	3bbtB-6cmjA: 21.8	3bbtB-6cmjA: 10.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	8	VAL A 205 ALA A 217 MET A 239 LEU A 250 THR A 264 LEU A 266 GLY A 270 LEU A 319	FKY A9001 ( 4.6A) FKY A9001 (-3.3A) FKY A9001 (-4.2A) None FKY A9001 (-3.0A) FKY A9001 (-4.4A) FKY A9001 (-3.3A) FKY A9001 ( 4.9A)	0.89A	3bbtB-6cz4A: 23.3	3bbtB-6cz4A: 14.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	8	VAL A 205 ALA A 217 MET A 239 LEU A 250 THR A 264 LEU A 266 LEU A 319 LEU A 333	FKY A9001 ( 4.6A) FKY A9001 (-3.3A) FKY A9001 (-4.2A) None FKY A9001 (-3.0A) FKY A9001 (-4.4A) FKY A9001 ( 4.9A) None	0.82A	3bbtB-6cz4A: 23.3	3bbtB-6cz4A: 14.24

[["3BBT_B_FMMB91_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"ALA A 428;LEU A 460;THR A 474;GLY A 480;LEU A 528;ASP A 539;PHE A 540","None","0.74A","3bbtB-1k2pA:29.3","3bbtB-1k2pA:34.78"],["3BBT_B_FMMB91_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",8,"VAL A 416;ALA A 428;MET A 449;LEU A 460;GLY A 480;LEU A 528;ASP A 539;PHE A 540","None","0.74A","3bbtB-1k2pA:29.3","3bbtB-1k2pA:34.78"],["3BBT_B_FMMB91_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;LEU A 251;THR A 266;GLY A 272;LEU A 321","None","0.68A","3bbtB-1k9aA:30.2","3bbtB-1k9aA:25.53"],["3BBT_B_FMMB91_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"VAL A  86;ALA A  99;GLY A 153;LEU A 201;ASP A 212;PHE A 213","ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A); MG A 536 (-3.3A);5EA A1001 (-3.6A)","0.29A","3bbtB-1s9iA:24.3","3bbtB-1s9iA:25.91"],["3BBT_B_FMMB91_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",7,"VAL A 377;ALA A 389;LEU A 421;GLY A 441;LEU A 489;ASP A 500;PHE A 501","None","0.70A","3bbtB-1snxA:24.4","3bbtB-1snxA:33.13"],["3BBT_B_FMMB91_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",6,"VAL A 603;ALA A 621;LEU A 656;THR A 670;GLY A 676;LEU A 799","STI A   3 ( 4.6A);STI A   3 (-3.5A);None;STI A   3 (-3.2A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.66A","3bbtB-1t46A:25.7","3bbtB-1t46A:29.83"],["3BBT_B_FMMB91_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"VAL X  25;ALA X  37;LEU X  69;THR X  82;GLY X  88;LEU X 137","STU X 902 ( 4.8A);STU X 902 (-3.1A);None;STU X 902 (-4.1A);STU X 902 (-3.5A);STU X 902 (-4.4A)","0.66A","3bbtB-2dq7X:23.8","3bbtB-2dq7X:36.12"],["3BBT_B_FMMB91_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"VAL A 281;ALA A 293;MET A 314;LEU A 325;THR A 338;GLY A 344;LEU A 393;ASP A 404;PHE A 405;LEU A 407","H8H A 534 (-4.4A);H8H A 534 (-3.2A);None;None;H8H A 534 (-3.1A);H8H A 534 (-3.3A);H8H A 534 (-4.5A);H8H A 534 (-4.2A);None;None","0.84A","3bbtB-2h8hA:32.9","3bbtB-2h8hA:23.02"],["3BBT_B_FMMB91_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"VAL A 281;ALA A 293;MET A 314;LEU A 325;THR A 338;GLY A 344;LEU A 393;ASP A 404;PHE A 405","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;None;QUE A   1 (-3.3A);QUE A   1 (-3.0A);QUE A   1 (-4.4A);None;None","0.83A","3bbtB-2hckA:31.7","3bbtB-2hckA:25.46"],["3BBT_B_FMMB91_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 281;MET A 314;THR A 338;GLY A 344;LEU A 393;ASP A 404;PHE A 405;LEU A 407","QUE A   1 ( 4.8A);None;QUE A   1 (-3.3A);QUE A   1 (-3.0A);QUE A   1 (-4.4A);None;None;None","1.09A","3bbtB-2hckA:31.7","3bbtB-2hckA:25.46"],["3BBT_B_FMMB91_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",6,"VAL A 259;ALA A 271;LEU A 303;THR A 316;GLY A 322;LEU A 371","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);None;1BM A 499 (-3.2A);1BM A 499 (-3.5A);1BM A 499 (-4.4A)","0.59A","3bbtB-2hk5A:24.1","3bbtB-2hk5A:34.33"],["3BBT_B_FMMB91_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"VAL A 256;ALA A 269;LEU A 301;THR A 315;GLY A 321;LEU A 370","GIN A 600 ( 4.7A);GIN A 600 (-3.1A);None;GIN A 600 (-3.4A);None;GIN A 600 (-4.7A)","0.63A","3bbtB-2hz0A:29.6","3bbtB-2hz0A:34.65"],["3BBT_B_FMMB91_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",9,"VAL A 352;ALA A 367;MET A 390;LEU A 401;GLY A 418;LEU A 468;ASP A 479;PHE A 480;LEU A 482","ANP A 615 (-4.5A);ANP A 615 (-3.3A);None;None;ANP A 615 ( 4.0A);ANP A 615 (-4.7A); MG A 614 ( 3.2A);None;None","1.16A","3bbtB-2ozoA:31.7","3bbtB-2ozoA:23.08"],["3BBT_B_FMMB91_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"VAL A 352;ALA A 367;MET A 390;LEU A 401;GLY A 419;LEU A 468;ASP A 479;PHE A 480","ANP A 615 (-4.5A);ANP A 615 (-3.3A);None;None;None;ANP A 615 (-4.7A); MG A 614 ( 3.2A);None","0.89A","3bbtB-2ozoA:31.7","3bbtB-2ozoA:23.08"],["3BBT_B_FMMB91_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",9,"VAL A 352;ALA A 367;MET A 390;LEU A 401;GLY A 420;LEU A 468;ASP A 479;PHE A 480;LEU A 482","ANP A 615 (-4.5A);ANP A 615 (-3.3A);None;None;ANP A 615 ( 3.9A);ANP A 615 (-4.7A); MG A 614 ( 3.2A);None;None","0.80A","3bbtB-2ozoA:31.7","3bbtB-2ozoA:23.08"],["3BBT_B_FMMB91_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",7,"VAL A  33;ALA A  46;LEU A  89;LEU A 105;GLY A 109;LEU A 156;THR A 166","ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;None;ATP A 381 ( 4.8A);ATP A 381 ( 4.6A)","0.39A","3bbtB-2phkA:21.7","3bbtB-2phkA:25.57"],["3BBT_B_FMMB91_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",7,"VAL A  33;ALA A  46;LEU A 105;GLY A 109;LEU A 156;THR A 166;PHE A 168","ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;ATP A 381 ( 4.8A);ATP A 381 ( 4.6A);None","0.80A","3bbtB-2phkA:21.7","3bbtB-2phkA:25.57"],["3BBT_B_FMMB91_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"VAL B  55;ALA B  67;LEU B 100;GLY B 120;LEU B 171;THR B 181","None","0.55A","3bbtB-2qkwB:18.3","3bbtB-2qkwB:25.00"],["3BBT_B_FMMB91_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"VAL A 204;ALA A 215;THR A 265;GLY A 271;LEU A 328;ASP A 339;PHE A 340","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);ADE A 488 (-4.3A);ADE A 488 ( 4.1A);ADE A 488 (-4.4A);None;None","0.90A","3bbtB-2qluA:24.5","3bbtB-2qluA:23.96"],["3BBT_B_FMMB91_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;LEU A 685;THR A 699;GLY A 705;LEU A 753","BME A   1 (-4.9A);PTR A 701 ( 4.7A);None;None;None;None","0.69A","3bbtB-2qobA:25.1","3bbtB-2qobA:35.49"],["3BBT_B_FMMB91_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",9,"MET A 772;LEU A 783;THR A 796;GLY A 802;LEU A 850;THR A 860;ASP A 861;PHE A 862;LEU A 864","GW7 A   1 ( 3.8A);GW7 A   1 (-3.9A);GW7 A   1 (-4.0A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A);GW7 A   1 (-3.8A);GW7 A   1 ( 4.7A)","0.81A","3bbtB-2r4bA:38.7","3bbtB-2r4bA:100.00"],["3BBT_B_FMMB91_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",11,"VAL A 732;ALA A 749;LEU A 783;THR A 796;LEU A 798;GLY A 802;LEU A 850;THR A 860;ASP A 861;PHE A 862;LEU A 864","GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-4.0A);GW7 A   1 (-4.5A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-3.5A);GW7 A   1 (-4.1A);GW7 A   1 (-3.8A);GW7 A   1 ( 4.7A)","0.64A","3bbtB-2r4bA:38.7","3bbtB-2r4bA:100.00"],["3BBT_B_FMMB91_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",6,"VAL A 234;ALA A 247;LEU A 303;GLY A 307;LEU A 354;THR A 367","XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.1A);XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A);XK9 A1511 (-3.7A)","0.58A","3bbtB-2xk9A:20.6","3bbtB-2xk9A:26.32"],["3BBT_B_FMMB91_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;LEU A 685;THR A 699;GLY A 705;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);None;Q9G A1898 (-3.5A);Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.58A","3bbtB-2xyuA:19.2","3bbtB-2xyuA:34.64"],["3BBT_B_FMMB91_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",6,"VAL A  38;ALA A  51;LEU A  93;LEU A 109;GLY A 113;LEU A 160","None;B49 A1294 (-3.2A);None;B49 A1294 ( 4.7A);B49 A1294 (-3.6A);B49 A1294 (-4.4A)","0.38A","3bbtB-2y7jA:22.2","3bbtB-2y7jA:21.55"],["3BBT_B_FMMB91_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",7,"VAL A  38;ALA A  51;LEU A 109;GLY A 113;LEU A 160;ASP A 171;PHE A 172","None;B49 A1294 (-3.2A);B49 A1294 ( 4.7A);B49 A1294 (-3.6A);B49 A1294 (-4.4A);B49 A1294 (-4.2A);None","0.87A","3bbtB-2y7jA:22.2","3bbtB-2y7jA:21.55"],["3BBT_B_FMMB91_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"VAL A  76;ALA A  92;LEU A 127;GLY A 147;LEU A 194;THR A 204;PHE A 206","None;STU A   1 (-3.3A);None;STU A   1 ( 3.9A);STU A   1 (-4.6A);STU A   1 (-3.6A);None","0.81A","3bbtB-2z7rA:21.9","3bbtB-2z7rA:24.52"],["3BBT_B_FMMB91_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 492;ALA A 512;GLY A 567;LEU A 630;ASP A 641;PHE A 642;LEU A 644","None;C4F A   1 (-3.3A);None;C4F A   1 (-4.6A);C4F A   1 (-4.5A);C4F A   1 ( 4.5A);None","1.06A","3bbtB-3c4fA:29.6","3bbtB-3c4fA:33.24"],["3BBT_B_FMMB91_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;LEU A 251;THR A 266;GLY A 272;LEU A 321","None","0.68A","3bbtB-3d7uA:24.8","3bbtB-3d7uA:33.85"],["3BBT_B_FMMB91_1","3dtc","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF07714(Pkinase_Tyr)",7,"VAL A 158;ALA A 169;LEU A 206;GLY A 226;LEU A 275;THR A 293;PHE A 295","VIN A6331 (-4.7A);VIN A6331 (-3.4A);None;VIN A6331 (-3.4A);VIN A6331 (-4.5A);VIN A6331 (-3.6A);None","0.59A","3bbtB-3dtcA:21.4","3bbtB-3dtcA:31.32"],["3BBT_B_FMMB91_1","3dxn","Toxoplasma gondii","CALMODULIN-LIKE DOMAIN PROTEIN KINASE ISOFORM 3","PF00069(Pkinase)",8,"VAL A  37;ALA A  50;LEU A  86;GLY A 106;LEU A 153;ASP A 167;PHE A 168;LEU A 170","None","0.76A","3bbtB-3dxnA:25.4","3bbtB-3dxnA:26.38"],["3BBT_B_FMMB91_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",6,"VAL A 439;ALA A 455;LEU A 489;LEU A 504;GLY A 508;LEU A 556","AGS A 999 (-4.6A);AGS A 999 (-3.6A);None;AGS A 999 (-4.4A);None;AGS A 999 (-4.5A)","0.62A","3bbtB-3fzpA:30.3","3bbtB-3fzpA:37.96"],["3BBT_B_FMMB91_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",8,"VAL A 234;ALA A 247;LEU A 303;GLY A 307;LEU A 354;THR A 367;ASP A 368;PHE A 369","None","0.72A","3bbtB-3i6uA:22.6","3bbtB-3i6uA:22.35"],["3BBT_B_FMMB91_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",7,"VAL A 704;LEU A 755;THR A 768;GLY A 774;LEU A 822;ASP A 833;PHE A 834","ANP A   1 (-3.9A);None;ANP A   1 ( 4.8A);ANP A   1 ( 4.9A);ANP A   1 (-4.7A); MG A1001 ( 3.1A);None","0.53A","3bbtB-3kexA:32.4","3bbtB-3kexA:58.41"],["3BBT_B_FMMB91_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;THR A 713;GLY A 719;LEU A 767;ASP A 778;PHE A 779","None;None;None;GOL A 403 (-3.4A);None;None;None","0.99A","3bbtB-3kulA:30.6","3bbtB-3kulA:32.58"],["3BBT_B_FMMB91_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",11,"ALA A 719;MET A 742;LEU A 753;THR A 766;LEU A 768;GLY A 772;LEU A 820;THR A 830;ASP A 831;PHE A 832;LEU A 834","ITI A   1 (-2.9A);ITI A   1 (-3.4A);ITI A   1 (-3.8A);ITI A   1 (-3.8A);ITI A   1 (-4.8A);ITI A   1 (-3.5A);ITI A   1 (-4.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.6A);ITI A   1 (-3.6A);None","0.92A","3bbtB-3lzbA:37.8","3bbtB-3lzbA:69.82"],["3BBT_B_FMMB91_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",11,"VAL A 702;ALA A 719;MET A 742;LEU A 753;THR A 766;LEU A 768;LEU A 820;THR A 830;ASP A 831;PHE A 832;LEU A 834","ITI A   1 (-4.8A);ITI A   1 (-2.9A);ITI A   1 (-3.4A);ITI A   1 (-3.8A);ITI A   1 (-3.8A);ITI A   1 (-4.8A);ITI A   1 (-4.6A);ITI A   1 (-3.8A);ITI A   1 ( 4.6A);ITI A   1 (-3.6A);None","0.92A","3bbtB-3lzbA:37.8","3bbtB-3lzbA:69.82"],["3BBT_B_FMMB91_1","3pg1","Leishmania major","MITOGEN-ACTIVATED PROTEIN KINASE, PUTATIVE (MAP KINASE-LIKE PROTEIN)","PF00069(Pkinase)",7,"ALA A  49;THR A 112;LEU A 114;LEU A 165;ASP A 176;PHE A 177;LEU A 179","None","0.96A","3bbtB-3pg1A:19.8","3bbtB-3pg1A:26.85"],["3BBT_B_FMMB91_1","3pls","Homo sapiens","MACROPHAGE-STIMULATING PROTEIN RECEPTOR","PF07714(Pkinase_Tyr)",8,"VAL A1096;ALA A1112;MET A1135;LEU A1146;GLY A1167;ASP A1226;PHE A1227;LEU A1229","ANP A1358 (-4.4A);ANP A1358 ( 3.8A);None;None;None; MG A   1 ( 3.2A);None;None","0.71A","3bbtB-3plsA:31.2","3bbtB-3plsA:35.62"],["3BBT_B_FMMB91_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",8,"ALA A 751;LEU A 785;LEU A 800;GLY A 804;LEU A 852;THR A 862;ASP A 863;PHE A 864","03Q A   1 (-3.1A);03Q A   1 (-3.1A);03Q A   1 (-4.6A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A);03Q A   1 (-3.3A);03Q A   1 (-4.0A);03Q A   1 (-4.2A)","0.92A","3bbtB-3pp0A:31.0","3bbtB-3pp0A:73.94"],["3BBT_B_FMMB91_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",8,"ALA A 751;LEU A 785;THR A 798;LEU A 800;GLY A 804;LEU A 852;THR A 862;PHE A 864","03Q A   1 (-3.1A);03Q A   1 (-3.1A);03Q A   1 (-4.1A);03Q A   1 (-4.6A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A);03Q A   1 (-3.3A);03Q A   1 (-4.2A)","0.81A","3bbtB-3pp0A:31.0","3bbtB-3pp0A:73.94"],["3BBT_B_FMMB91_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",8,"VAL A 734;ALA A 751;LEU A 785;LEU A 800;GLY A 804;LEU A 852;THR A 862;ASP A 863","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-3.1A);03Q A   1 (-4.6A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A);03Q A   1 (-3.3A);03Q A   1 (-4.0A)","0.68A","3bbtB-3pp0A:31.0","3bbtB-3pp0A:73.94"],["3BBT_B_FMMB91_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",8,"VAL A 734;ALA A 751;LEU A 785;THR A 798;LEU A 800;GLY A 804;LEU A 852;THR A 862","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-3.1A);03Q A   1 (-4.1A);03Q A   1 (-4.6A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A);03Q A   1 (-3.3A)","0.40A","3bbtB-3pp0A:31.0","3bbtB-3pp0A:73.94"],["3BBT_B_FMMB91_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",8,"VAL A 734;ALA A 751;MET A 774;THR A 798;LEU A 800;GLY A 804;LEU A 852;THR A 862","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.5A);03Q A   1 (-4.1A);03Q A   1 (-4.6A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A);03Q A   1 (-3.3A)","1.12A","3bbtB-3pp0A:31.0","3bbtB-3pp0A:73.94"],["3BBT_B_FMMB91_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",7,"VAL A 565;ALA A 576;THR A 625;GLY A 631;LEU A 683;ASP A 694;PHE A 695","STU A   1 (-4.9A);STU A   1 (-3.3A);STU A   1 (-4.1A);STU A   1 (-3.2A);STU A   1 (-4.3A);STU A   1 (-3.5A);None","0.89A","3bbtB-3ppzA:28.0","3bbtB-3ppzA:30.12"],["3BBT_B_FMMB91_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",6,"VAL A 303;ALA A 315;LEU A 349;GLY A 369;LEU A 423;ASP A 434","None","0.69A","3bbtB-3ulzA:22.0","3bbtB-3ulzA:27.70"],["3BBT_B_FMMB91_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",6,"VAL A  83;ALA A  96;GLY A 150;LEU A 198;ASP A 209;PHE A 210","ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 ( 4.3A);ANP A 401 (-4.8A); MG A 402 (-3.2A);CHU A 403 (-3.8A)","0.37A","3bbtB-3wigA:17.4","3bbtB-3wigA:25.84"],["3BBT_B_FMMB91_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;GLY A 922;LEU A1035;ASP A1046;PHE A1047;LEU A1049","LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.4A);LEV A1201 (-3.3A);LEV A1201 ( 4.5A)","0.80A","3bbtB-3wzdA:29.5","3bbtB-3wzdA:32.29"],["3BBT_B_FMMB91_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;LEU A 889;GLY A 922;LEU A1035;ASP A1046;LEU A1049","LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 ( 4.4A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.4A);LEV A1201 ( 4.5A)","1.02A","3bbtB-3wzdA:29.5","3bbtB-3wzdA:32.29"],["3BBT_B_FMMB91_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"VAL A 633;ALA A 649;LEU A 683;THR A 697;GLY A 703;LEU A 751","None","0.65A","3bbtB-3zfxA:31.1","3bbtB-3zfxA:35.12"],["3BBT_B_FMMB91_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"VAL A 222;ALA A 233;THR A 283;GLY A 289;LEU A 343;ASP A 354","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 (-3.6A);TAK A1507 (-3.5A);TAK A1507 (-4.7A);TAK A1507 (-3.5A)","0.61A","3bbtB-4c02A:18.9","3bbtB-4c02A:23.90"],["3BBT_B_FMMB91_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",7,"VAL A 254;ALA A 267;GLY A 324;LEU A 371;THR A 381;ASP A 382;PHE A 383","None","0.97A","3bbtB-4c0tA:20.2","3bbtB-4c0tA:15.15"],["3BBT_B_FMMB91_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"VAL A 575;ALA A 588;LEU A 622;LEU A 638;GLY A 642;LEU A 690","GUI A 901 (-4.5A);GUI A 901 (-3.4A);None;GUI A 901 (-4.4A);GUI A 901 (-3.5A);GUI A 901 (-4.3A)","0.67A","3bbtB-4e93A:31.2","3bbtB-4e93A:27.27"],["3BBT_B_FMMB91_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",7,"VAL A 575;ALA A 588;LEU A 638;GLY A 642;LEU A 690;ASP A 701;PHE A 702","GUI A 901 (-4.5A);GUI A 901 (-3.4A);GUI A 901 (-4.4A);GUI A 901 (-3.5A);GUI A 901 (-4.3A);GUI A 901 ( 4.1A);None","0.93A","3bbtB-4e93A:31.2","3bbtB-4e93A:27.27"],["3BBT_B_FMMB91_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",8,"VAL A 385;ALA A 400;MET A 424;GLY A 454;LEU A 501;ASP A 512;PHE A 513;LEU A 515","ANP A 701 (-4.1A);ANP A 701 (-3.3A);None;ANP A 701 ( 4.2A);ANP A 701 (-4.5A); MG A 702 ( 3.1A);None;None","0.61A","3bbtB-4fl3A:32.9","3bbtB-4fl3A:22.08"],["3BBT_B_FMMB91_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A1130;ALA A1148;LEU A1198;GLY A1202;LEU A1256;PHE A1271","0UV A1501 (-4.5A);0UV A1501 (-3.4A);0UV A1501 ( 4.8A);0UV A1501 (-3.6A);0UV A1501 (-4.6A);None","0.69A","3bbtB-4fodA:28.6","3bbtB-4fodA:32.30"],["3BBT_B_FMMB91_1","4fr4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 32A","PF00069(Pkinase)",6,"VAL A  37;ALA A  50;LEU A  86;LEU A 102;GLY A 106;THR A 163","STU A 401 ( 4.9A);STU A 401 (-3.2A);None;STU A 401 (-4.4A);STU A 401 ( 3.7A);STU A 401 (-3.8A)","0.70A","3bbtB-4fr4A:19.8","3bbtB-4fr4A:25.00"],["3BBT_B_FMMB91_1","4fr4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 32A","PF00069(Pkinase)",7,"VAL A  37;ALA A  50;LEU A 102;GLY A 106;LEU A 153;THR A 163;PHE A 165","STU A 401 ( 4.9A);STU A 401 (-3.2A);STU A 401 (-4.4A);STU A 401 ( 3.7A);STU A 401 (-4.7A);STU A 401 (-3.8A);None","0.81A","3bbtB-4fr4A:19.8","3bbtB-4fr4A:25.00"],["3BBT_B_FMMB91_1","4g3f","Mus musculus","NF-KAPPA-BETA-INDUCING KINASE","PF00069(Pkinase)",7,"VAL A 416;ALA A 429;LEU A 457;LEU A 473;GLY A 477;LEU A 524;PHE A 537","0WB A 701 (-4.4A);0WB A 701 (-3.3A);None;0WB A 701 (-4.3A);0WB A 701 ( 4.5A);0WB A 701 (-4.3A);None","0.99A","3bbtB-4g3fA:23.3","3bbtB-4g3fA:24.23"],["3BBT_B_FMMB91_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",9,"VAL A 140;ALA A 156;MET A 181;LEU A 192;GLY A 211;LEU A 259;ASP A 270;PHE A 271;LEU A 273","None","0.53A","3bbtB-4hzsA:23.7","3bbtB-4hzsA:36.31"],["3BBT_B_FMMB91_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",9,"VAL A 140;ALA A 156;MET A 181;LEU A 192;LEU A 207;GLY A 211;LEU A 259;ASP A 270;LEU A 273","None","0.73A","3bbtB-4hzsA:23.7","3bbtB-4hzsA:36.31"],["3BBT_B_FMMB91_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",9,"VAL A 140;ALA A 156;MET A 181;LEU A 192;THR A 205;GLY A 211;LEU A 259;ASP A 270;PHE A 271","None","0.69A","3bbtB-4hzsA:23.7","3bbtB-4hzsA:36.31"],["3BBT_B_FMMB91_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",9,"VAL A 140;ALA A 156;MET A 181;LEU A 192;THR A 205;LEU A 207;GLY A 211;LEU A 259;ASP A 270","None","0.84A","3bbtB-4hzsA:23.7","3bbtB-4hzsA:36.31"],["3BBT_B_FMMB91_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"VAL A 140;ALA A 156;LEU A 192;THR A 205;LEU A 207;GLY A 211;LEU A 259","1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 ( 3.8A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.9A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.77A","3bbtB-4id7A:30.2","3bbtB-4id7A:36.67"],["3BBT_B_FMMB91_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",7,"VAL A 140;ALA A 156;THR A 205;LEU A 207;GLY A 211;LEU A 259;PHE A 271","1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.9A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A);1G0 A 401 ( 4.8A)","0.97A","3bbtB-4id7A:30.2","3bbtB-4id7A:36.67"],["3BBT_B_FMMB91_1","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",7,"VAL A 414;ALA A 427;LEU A 455;LEU A 471;GLY A 475;LEU A 522;PHE A 535","T28 A 701 (-4.7A);T28 A 701 (-3.0A);None;T28 A 701 ( 4.8A);T28 A 701 ( 3.0A);T28 A 701 (-3.9A);None","0.97A","3bbtB-4idtA:22.8","3bbtB-4idtA:25.06"],["3BBT_B_FMMB91_1","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",7,"VAL A 414;ALA A 427;LEU A 455;LEU A 471;LEU A 522;ASP A 534;PHE A 535","T28 A 701 (-4.7A);T28 A 701 (-3.0A);None;T28 A 701 ( 4.8A);T28 A 701 (-3.9A);T28 A 701 ( 3.4A);None","1.02A","3bbtB-4idtA:22.8","3bbtB-4idtA:25.06"],["3BBT_B_FMMB91_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"VAL A 281;ALA A 293;MET A 314;LEU A 325;GLY A 344;LEU A 393;ASP A 404;PHE A 405;LEU A 407","0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);None;None;0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A);0J9 A 601 (-3.1A);None;None","0.63A","3bbtB-4k11A:33.0","3bbtB-4k11A:25.75"],["3BBT_B_FMMB91_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",10,"VAL A  36;ALA A  49;MET A  65;LEU A  76;THR A  95;GLY A 101;LEU A 150;ASP A 161;PHE A 162;LEU A 164","ANP A 401 (-4.5A);ANP A 401 (-3.1A);None;None;ANP A 401 (-3.8A);None;ANP A 401 (-4.8A); MG A 403 ( 3.1A);None;None","0.75A","3bbtB-4m69A:27.3","3bbtB-4m69A:25.71"],["3BBT_B_FMMB91_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"VAL A  54;ALA A  67;THR A 123;LEU A 125;GLY A 128;LEU A 180;PHE A 192","None;SIN A 401 ( 3.7A);None;SIN A 401 ( 4.8A);SIN A 401 (-3.5A);SIN A 401 ( 4.5A);None","0.77A","3bbtB-4o38A:18.5","3bbtB-4o38A:24.66"],["3BBT_B_FMMB91_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 627;ALA A 644;LEU A 678;THR A 692;GLY A 698;LEU A 746","None","0.61A","3bbtB-4p2kA:29.9","3bbtB-4p2kA:35.94"],["3BBT_B_FMMB91_1","4uy9","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF00069(Pkinase)",7,"VAL A 158;ALA A 169;GLY A 226;LEU A 275;THR A 293;ASP A 294;PHE A 295","None","0.74A","3bbtB-4uy9A:27.1","3bbtB-4uy9A:33.89"],["3BBT_B_FMMB91_1","4uya","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4","PF07714(Pkinase_Tyr)",6,"VAL A 138;ALA A 149;GLY A 206;LEU A 270;THR A 288;PHE A 290","AGS A1438 (-4.4A);AGS A1438 (-3.4A);None;AGS A1438 (-4.7A);AGS A1438 ( 4.7A);None","0.62A","3bbtB-4uyaA:26.6","3bbtB-4uyaA:34.72"],["3BBT_B_FMMB91_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",6,"VAL B 275;ALA B 288;LEU B 320;THR B 334;GLY B 340;LEU B 389","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.63A","3bbtB-4xeyB:25.0","3bbtB-4xeyB:29.77"],["3BBT_B_FMMB91_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"VAL A 416;ALA A 428;MET A 449;LEU A 460;THR A 474;GLY A 480;LEU A 528;ASP A 539;PHE A 540;LEU A 542","None","0.87A","3bbtB-4xi2A:30.9","3bbtB-4xi2A:25.77"],["3BBT_B_FMMB91_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",9,"VAL A 416;ALA A 428;MET A 449;LEU A 460;THR A 474;GLY A 480;LEU A 528;ASP A 539;PHE A 540","746 A 702 ( 4.3A);746 A 702 (-2.4A);None;None;746 A 702 (-3.7A);746 A 702 (-3.6A);746 A 702 (-4.4A);746 A 702 (-3.7A);None","0.75A","3bbtB-4y93A:31.5","3bbtB-4y93A:24.09"],["3BBT_B_FMMB91_1","4yc6","Homo sapiens","CYCLIN-DEPENDENT KINASE 1","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;LEU A  66;LEU A 135;ASP A 146;PHE A 147","None","0.60A","3bbtB-4yc6A:24.6","3bbtB-4yc6A:24.70"],["3BBT_B_FMMB91_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",7,"VAL A 477;ALA A 488;THR A 539;GLY A 545;LEU A 595;ASP A 606;PHE A 607","None;4CV A 801 (-3.5A);4CV A 801 (-2.8A);4CV A 801 ( 4.0A);4CV A 801 (-4.4A);4CV A 801 (-3.5A);None","1.10A","3bbtB-4yffA:24.9","3bbtB-4yffA:27.67"],["3BBT_B_FMMB91_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",7,"VAL A 492;ALA A 512;GLY A 567;LEU A 630;ASP A 641;PHE A 642;LEU A 644","38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 (-3.4A);38O A1769 (-4.6A);38O A1769 (-4.0A);EDO A1766 (-3.7A);None","0.85A","3bbtB-5a46A:27.2","3bbtB-5a46A:34.84"],["3BBT_B_FMMB91_1","5d7a","Homo sapiens","TRAF2 AND NCK-INTERACTING PROTEIN KINASE","PF00069(Pkinase)",6,"VAL A  39;ALA A  52;GLY A 111;LEU A 160;ASP A 171;PHE A 172","VAL A  39 (-0.6A);ALA A  52 (-0.0A);GLY A 111 (-0.0A);LEU A 160 (-0.6A);ASP A 171 ( 0.5A);PHE A 172 ( 1.3A)","0.55A","3bbtB-5d7aA:24.1","3bbtB-5d7aA:25.90"],["3BBT_B_FMMB91_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"VAL A 607;ALA A 625;LEU A 660;THR A 674;GLY A 680;LEU A 825","748 A1001 ( 4.7A);748 A1001 (-3.7A);None;748 A1001 (-3.2A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.64A","3bbtB-5grnA:23.6","3bbtB-5grnA:30.69"],["3BBT_B_FMMB91_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",6,"VAL A  28;ALA A  41;LEU A  76;LEU A  92;GLY A  96;LEU A 143","ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;ADP A 301 ( 4.8A);None;ADP A 301 (-4.7A)","0.66A","3bbtB-5hu3A:23.0","3bbtB-5hu3A:25.15"],["3BBT_B_FMMB91_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"ALA A 743;LEU A 792;GLY A 796;LEU A 844;THR A 854;ASP A 855;PHE A 856","6HJ A1101 (-3.1A);6HJ A1101 ( 4.9A);6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A);6HJ A1101 (-4.3A);None","0.89A","3bbtB-5j9zA:32.8","3bbtB-5j9zA:77.54"],["3BBT_B_FMMB91_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 726;ALA A 743;LEU A 777;LEU A 792;GLY A 796;LEU A 844;THR A 854","6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);None;6HJ A1101 ( 4.9A);6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A)","0.65A","3bbtB-5j9zA:32.8","3bbtB-5j9zA:77.54"],["3BBT_B_FMMB91_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 726;ALA A 743;LEU A 792;GLY A 796;LEU A 844;THR A 854;PHE A 856","6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 ( 4.9A);6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A);6HJ A1101 (-3.9A);None","0.85A","3bbtB-5j9zA:32.8","3bbtB-5j9zA:77.54"],["3BBT_B_FMMB91_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",6,"VAL A 404;ALA A 417;LEU A 451;LEU A 467;GLY A 471;LEU A 518","GUI A 701 (-4.4A);GUI A 701 ( 3.9A);None;GUI A 701 ( 4.7A);GUI A 701 (-3.6A);GUI A 701 (-4.4A)","0.55A","3bbtB-5jznA:22.1","3bbtB-5jznA:25.50"],["3BBT_B_FMMB91_1","5kkr","Homo sapiens","KINASE SUPPRESSOR OF RAS 2","PF07714(Pkinase_Tyr)",6,"VAL B 680;ALA B 690;THR B 739;LEU B 741;THR B 802;PHE B 804","6U7 B1001 ( 4.3A);6U7 B1001 (-3.6A);6U7 B1001 (-4.0A);6U7 B1001 (-4.6A);6U7 B1001 (-3.6A);6U7 B1001 (-3.8A)","0.65A","3bbtB-5kkrB:24.7","3bbtB-5kkrB:27.87"],["3BBT_B_FMMB91_1","5loh","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE GREATWALL,SERINE\/THREONINE-PROTEIN KINASE GREATWALL","PF00069(Pkinase)",7,"VAL A  49;ALA A  60;LEU A  96;GLY A 116;LEU A 163;THR A 173;PHE A 175","None;STU A 901 (-3.3A);None;STU A 901 (-3.5A);STU A 901 (-4.5A);STU A 901 (-3.5A);None","0.63A","3bbtB-5lohA:17.7","3bbtB-5lohA:24.66"],["3BBT_B_FMMB91_1","5vcx","Homo sapiens","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","PF00069(Pkinase)",8,"VAL A 124;ALA A 137;LEU A 173;THR A 187;LEU A 189;GLY A 191;ASP A 251;PHE A 252","H8H A 401 (-4.7A);H8H A 401 (-3.3A);None;H8H A 401 (-3.5A);None;H8H A 401 (-4.4A);EDO A 402 ( 2.9A);None","1.29A","3bbtB-5vcxA:17.3","3bbtB-5vcxA:23.39"],["3BBT_B_FMMB91_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",9,"VAL A 899;ALA A 917;MET A 938;THR A 963;GLY A 969;LEU A1017;THR A1027;ASP A1028;PHE A1029","ANP A1201 (-4.4A);ANP A1201 (-3.3A);None;ANP A1201 (-3.9A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A);ANP A1201 ( 4.9A); MG A1202 ( 3.0A);None","0.56A","3bbtB-5wnoA:35.4","3bbtB-5wnoA:17.07"],["3BBT_B_FMMB91_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",9,"VAL A 899;ALA A 917;THR A 963;GLY A 969;LEU A1017;THR A1027;ASP A1028;PHE A1029;LEU A1031","ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.9A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A);ANP A1201 ( 4.9A); MG A1202 ( 3.0A);None;None","0.73A","3bbtB-5wnoA:35.4","3bbtB-5wnoA:17.07"],["3BBT_B_FMMB91_1","5xzw","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE RAD53","no annotation",7,"VAL A 212;ALA A 225;GLY A 279;LEU A 326;THR A 338;ASP A 339;PHE A 340","None","1.04A","3bbtB-5xzwA:18.9","3bbtB-5xzwA:20.11"],["3BBT_B_FMMB91_1","5xzw","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE RAD53","no annotation",7,"VAL A 212;LEU A 248;GLY A 279;LEU A 326;THR A 338;ASP A 339;PHE A 340","None","1.32A","3bbtB-5xzwA:18.9","3bbtB-5xzwA:20.11"],["3BBT_B_FMMB91_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",7,"VAL A  41;ALA A  54;MET A  74;GLY A 105;LEU A 153;ASP A 164;PHE A 165","ANP A 501 (-4.4A);ANP A 501 ( 3.7A);None;ANP A 501 ( 4.0A);ANP A 501 (-4.6A); MG A 502 ( 3.1A);None","0.60A","3bbtB-6ao5A:23.6","3bbtB-6ao5A:26.23"],["3BBT_B_FMMB91_1","6b2q","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNA","no annotation",7,"VAL A  27;ALA A  40;LEU A  97;GLY A 100;LEU A 148;THR A 158;PHE A 160","CJJ A 301 (-4.6A);CJJ A 301 (-3.5A);None;CJJ A 301 (-4.2A);CJJ A 301 (-4.5A);CJJ A 301 (-3.1A);None","1.17A","3bbtB-6b2qA:23.5","3bbtB-6b2qA:13.41"],["3BBT_B_FMMB91_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",6,"VAL A 179;ALA A 192;LEU A 251;LEU A 269;GLY A 273;LEU A 319","BI9 A 501 ( 4.8A);BI9 A 501 (-3.3A);None;BI9 A 501 (-4.4A);BI9 A 501 (-3.3A);BI9 A 501 (-4.7A)","0.55A","3bbtB-6bqlA:20.9","3bbtB-6bqlA:12.20"],["3BBT_B_FMMB91_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",6,"VAL A 142;ALA A 155;LEU A 214;LEU A 232;GLY A 236;LEU A 282","H1N A 501 (-4.4A);H1N A 501 (-3.4A);None;H1N A 501 (-4.3A);H1N A 501 (-3.6A);H1N A 501 (-4.8A)","0.42A","3bbtB-6ccfA:23.2","3bbtB-6ccfA:13.98"],["3BBT_B_FMMB91_1","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",6,"VAL A 179;ALA A 192;LEU A 251;LEU A 269;GLY A 273;LEU A 319","F6J A 501 (-4.6A);F6J A 501 (-3.4A);None;F6J A 501 ( 4.4A);F6J A 501 ( 3.7A);F6J A 501 (-4.5A)","0.64A","3bbtB-6cmjA:21.8","3bbtB-6cmjA:10.67"],["3BBT_B_FMMB91_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",8,"VAL A 205;ALA A 217;MET A 239;LEU A 250;THR A 264;LEU A 266;GLY A 270;LEU A 319","FKY A9001 ( 4.6A);FKY A9001 (-3.3A);FKY A9001 (-4.2A);None;FKY A9001 (-3.0A);FKY A9001 (-4.4A);FKY A9001 (-3.3A);FKY A9001 ( 4.9A)","0.89A","3bbtB-6cz4A:23.3","3bbtB-6cz4A:14.24"],["3BBT_B_FMMB91_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",8,"VAL A 205;ALA A 217;MET A 239;LEU A 250;THR A 264;LEU A 266;LEU A 319;LEU A 333","FKY A9001 ( 4.6A);FKY A9001 (-3.3A);FKY A9001 (-4.2A);None;FKY A9001 (-3.0A);FKY A9001 (-4.4A);FKY A9001 ( 4.9A);None","0.82A","3bbtB-6cz4A:23.3","3bbtB-6cz4A:14.24"]]